FACTORS INFLUENCING QUALITY OF LIFE OF PATIENTS WITH CHRONIC SCHIZOPHRENIA IN A LONG-STAY PSYCHYATRIC FACILITY

Aleksandra Petrovic Kitic

doi:10.5937/sjecr15-5286

Aleksandra Petrovic Kitic Faculty of Medical Sciences, Kragujevac.

DOI: https://doi.org/10.5937/sjecr15-5286

Sažetak

Introduction: Many factors concomitantly influence quality of life of the patients with chronic schizophrenia in a long-stay psychiatric facility. Appropriate selection of antipsychotics and intensity of their harmful effects have significant influence on life quality of these patients. The aim of this study was to identify the most significant factors which have effect on the life quality of the patients with chronic schizophrenia. Methods: The study included 102 beneficiaries at the Institution for Accommodation of Adults “Male Pčelice” Kragujevac. The patients were interviewed in a single, selected day by using the questionnaire issued by World Health Organization. The specified data were obtained from health files of the beneficiaries. Results: The patients who were receiving only atypical antipsychotic had better physical health quality of life score in comparison to those who received the combination of antipsychotics (77.14 vs. 68.57; U = 332.0; p = 0.02) There was statistically significant difference in the domain of mental health quality of life depending on the group of antipsychotics which were administered (31.96 vs. 55.27 vs. 49.46; c2 = 7.02; p = 0.03). Conclusion: the patients who were receiving atypical antipsychotics had better life quality in comparison to those who received typical antipsychotics, possible due to better safety profile of atypical antipsychotics and better feeling of individual pleasure.

Reference

Chan GW, Ungvari GS, Shek DT, Leung Dagger JJ. Hospital and community-based care for patients with chronic schizophrenia in Hong Kong- quality of life and its correlates. Soc Psychiatry Psychiatr Epidemiol 2003; 38(4): 196-203.

Salomé F, Petitjean F, Germain C, Demant JC. The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients' expectations. A comparative study. Encephale 2004; 30(1): 60-8.

Rössler W, Salize HJ, Cucchiaro G, Reinhard I, Kernig C. Does the place of treatment influence the quality of life of schizophrenics? Acta Psychiatr Scand. 1999; 100(2): 142-8.

Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Curr Med Res Opin. 2010; 26(4): 787-801.

Kane JM, Kim E, Kan HJ, Guo Z, Bates JA, Whitehead R, Pikalov A. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy. 2009; 7(2): 109-19.

Bebbington PE, Angermeyer M, Azorin JM, Marwaha S, Marteau F, Toumi M. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl. 2009; 438: 22-8.

World Health Organization. ICD-10 Chapter V. Diagnostic Criteria for Research. Genova: WHO, 1993.

Zaghdoudi L, Homri W, Belaid S, Ben Bechir M, Labbane R. Quality of life of patient with schizophrenia treated by conventional and atypical neuroleptics. Tunis Med. 2009; 87(9): 593-8.

Zhang PL, Santos JM, Newcomer J, Pelfrey BA, Johnson MC. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res. 2004; 71(1): 137-44.

Midori Fujikawa, Takashi Togo, Asuka Yoshimi et al. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Progress in Neuro Psychopharmacology & Biological Psychiatry 2008; 32: 755–760.

Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003; 54: 719–23.

Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A,Wagner T, et al. Prediction of remission as a combination of symptomatic and functionalremission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006; 67: 1690–7.

Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents. Am J Psychiatry 2002; 159: 103–8.

Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psichiatry 2003; 18(5): 432-40.

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87.

Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36: 105–12.

Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004; 65: 354–60.